Search Results - Piruzeli, Maria Lucia Buziqui

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

    The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis by Soung, Jennifer, Laquer, Vivian, Merola, Joseph F., Moore, Angela, Elmaraghy, Hany, Hu, Chaoran, Piruzeli, Maria Lucia Buziqui, Pierce, Evangeline, Garcia Gil, Esther, Jarell, Abel D.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials

    52041 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: integrated analysis from 10 clinical trials by Gold, Linda Stein, Thaci, Diamant, Katoh, Norito, Shi, Vivian, Irvine, Alan, Buziqui Piruzeli, Maria Lucia, Montmayeur, Sonia, Gallo, Gaia, de Bruin-Weller, Marjolein

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age

    626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age by Armstrong, April, Zirwas, Matthew, Napolitano, Maddalena, Torres, Tiago, Staumont-Salle, Delphine, Atwater, Amber Reck, Dossenbach, Martin, Agell, Helena, Chen, Sherry, Qiao, Meihua, Pierce, Evangeline, Piruzeli, Maria Lucia Buziqui, Mostaghimi, Arash

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

    494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis by Guttman-Yassky, Emma, Weidinger, Stephan, Simpson, Eric, Gooderham, Melinda, Irvine, Alan, Spelman, Lynda, Silverberg, Jonathan, Elmaraghy, Hany, DeLuca-Carter, Louise, Piruzeli, Maria Lucia Buziqui, Hu, Chaoran, Yang, Fan Emily, Pierce, Evangeline, Bardolet, Laia, Thaci, Diamant

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis

    Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis by Guttman-Yassky, Emma, Weidinger, Stephan, Simpson, Eric, Gooderham, Melinda, Irvine, Alan, Spelman, Lynda, Silverberg, Jonathan, Elmaraghy, Hany, DeLuca-Carter, Louise, Buziqui Piruzeli, Maria Lucia, Hu, Chaoran, Yang, Fan Emily, Pierce, Evangeline, Bardolet, Laia, Thaci, Diamant

    Published in Skin (Milwood, N.Y.)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo

    Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo by Murase, Jenny E., Munera-Campos, Monica, Hong, H. Chih-ho, Taieb, Alain, Chung, Wen-Hung, Reck Atwater, Amber, Rueda, Maria Jose, Zhong, Jinglin, Buziqui Piruzeli, Maria Lucia, Pau-Charles, Ignasi, Deleuran, Mette

    Published in Skin (Milwood, N.Y.)
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: